Title: Compulsory licence for diabetes drug: Legality of Lee Pharma's application
Loading...
Date
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Economic and Political Weekly
Abstract
This article examines the legality of the Indian pharmaceutical company Lee Pharma's application for compulsory licence for Saxagliptin (Onglyza and Kombiglyze), an anti-diabetes drug, the patent for which is held by the Swedish multinational company AstraZeneca. What are the merits of the prima facie view taken by the controller of patents and the possibility of Lee Pharma getting the licence under the Indian patents law?